Skip to main content
Smart Investors Daily
BioGaia AB (publ) logo

OTC · BIOGY

BioGaia AB (publ)

Healthcare · Drug Manufacturers - Specialty & Generic

$12.45

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 8:54 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.05B
P/E ratio
31.59
Dividend yield
5.69%
52-week range
— – —
Volume
1
Avg. volume
891

Price performance · BIOGY

BIOGY price history

1M range · 0 trading sessions · Daily adjusted prices

BIOGY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest BIOGY news

The latest Smart Investors Daily articles mentioning BIOGY.

BIOGY research

Overview

Company profile and research snapshot.

Company profile

BIOGAIA AB S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$10.84
Implied upside
—
Analysts
5
BIOGY recent ratings
DateFirmRatingTarget
Jul 20, 2026DNB CARNEGIEBuy—
Jul 6, 2026DNB CARNEGIEBuy—
Jul 5, 2026DNB CARNEGIEBuy—
Jun 18, 2026HANDELSBANKEN CAPITAL MARKETSBuy—
Jun 17, 2026HANDELSBANKEN CAPITAL MARKETSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 18, 2026

BioGaia (OM:BIOG B) Stock Looks Undervalued With 29% Upside To Fair Value

BioGaia shares have delivered solid gains over several time frames, so the immediate question for anyone looking at the stock today is whether that price strength lines up with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the focus turns squarely to what its future cash flows might justify. BioGaia has returned 48.8% over the past 5 years, which puts real weight on whether current buyers are paying an appropriate price for those cash...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.